Ramos M.
201
Coauthors
14
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2001 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Inmunología | 11 |
| Cáncer | 8 |
| Medicina interna | 4 |
| Farmacología | 2 |
| Ensayo clínico | 2 |
| Infección | 1 |
| Cuidado de la salud | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 14 |
| Farmacología y terapéutica | 8 |
| Medicina y salud | 6 |
| Microorganismos, hongos y algas | 3 |
| Problemas sociales y servicios a grupos | 2 |
| Mammalia | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 14 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 13 |
| Saavedra Hernández D. | 5 |
| Mazorra Z. | 4 |
| Cepeda M. | 3 |
| Sánchez N. | 3 |
| Leon K. | 3 |
| Caballero A. | 3 |
| Lorenzo G. | 3 |
| Añe-Kouri A.L. | 3 |
| Filgueira L.M. | 3 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Nimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopusQuality of life assessment as a pbkp_redictor of survival in cancer
ArticleAbstract: The quality of life and survival are variables to take into account in the clinical trial of oncologPalabras claves:clinical trials, Oncology, quality of life, SurvivalAutores:Aliuska Frías, Ballesteros J., Bouza-Herrera C.N., Carmen Elena Viada, García L., Mabel Álvarez, Martha M. Fors-López, Ramos M., Santiesteban Y.Fuentes:scopusA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusShort communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
ArticleAbstract: High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas anPalabras claves:Autores:Figueredo R., Iznaga N., Lage Davila A., Menéndez A., Pérez R., Ramos M., Rodríguez V., Stevenson A., Tania Crombet, Torres F., Torres O., Veitía I.Fuentes:scopus